10-Q 1 ipsc-20240331x10q.htm 10-Q
http://www.centurytx.com/20240331#AccruedExpensesAndOtherLiabilitiesCurrenthttp://www.centurytx.com/20240331#AccruedExpensesAndOtherLiabilitiesCurrent0001850119false--12-312024Q100http://fasb.org/us-gaap/2023#PrepaidExpenseAndOtherAssetsCurrenthttp://fasb.org/us-gaap/2023#PrepaidExpenseAndOtherAssetsCurrent60335701603357010http://www.centurytx.com/20240331#AccruedExpensesAndOtherLiabilitiesCurrentP5Yhttp://www.centurytx.com/20240331#AccruedExpensesAndOtherLiabilitiesCurrentP4Y0001850119us-gaap:RetainedEarningsMember2024-03-310001850119us-gaap:AdditionalPaidInCapitalMember2024-03-310001850119us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310001850119us-gaap:RetainedEarningsMember2023-12-310001850119us-gaap:AdditionalPaidInCapitalMember2023-12-310001850119us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001850119us-gaap:RetainedEarningsMember2023-03-310001850119us-gaap:AdditionalPaidInCapitalMember2023-03-310001850119us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001850119us-gaap:RetainedEarningsMember2022-12-310001850119us-gaap:AdditionalPaidInCapitalMember2022-12-310001850119us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001850119us-gaap:CommonStockMember2024-03-310001850119us-gaap:CommonStockMember2023-12-310001850119us-gaap:CommonStockMember2023-03-310001850119us-gaap:CommonStockMember2022-12-310001850119us-gaap:EmployeeStockOptionMember2023-12-310001850119us-gaap:EmployeeStockOptionMemberipsc:IncentivePlan2021Member2024-01-012024-03-310001850119us-gaap:EmployeeStockOptionMember2024-03-310001850119ipsc:EmployeeStockPurchasePlan2021Member2024-03-310001850119ipsc:IncentivePlan2021Member2023-12-310001850119ipsc:EmployeeStockPurchasePlan2021Member2023-12-310001850119us-gaap:EmployeeStockOptionMemberipsc:IncentivePlan2021Member2021-06-170001850119us-gaap:EmployeeStockOptionMember2023-01-012023-12-310001850119us-gaap:RestrictedStockUnitsRSUMember2023-12-310001850119ipsc:UnvestedRestrictedStockWithTimeBasedVestingMember2023-12-310001850119us-gaap:RestrictedStockUnitsRSUMemberipsc:IncentivePlan2021Member2024-01-012024-03-310001850119ipsc:PerformanceBasedRestrictedStockUnitsMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2024-01-012024-03-310001850119ipsc:PerformanceBasedRestrictedStockUnitsMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2024-01-012024-03-3100018501192022-01-070001850119us-gaap:ResearchAndDevelopmentExpenseMember2023-12-310001850119us-gaap:GeneralAndAdministrativeExpenseMember2023-12-310001850119us-gaap:EmployeeSeveranceMember2023-12-310001850119us-gaap:EmployeeSeveranceMember2024-03-310001850119us-gaap:SoftwareDevelopmentMember2024-03-310001850119us-gaap:LeaseholdImprovementsMember2024-03-310001850119us-gaap:FurnitureAndFixturesMember2024-03-310001850119ipsc:LabEquipmentMember2024-03-310001850119us-gaap:SoftwareDevelopmentMember2023-12-310001850119us-gaap:LeaseholdImprovementsMember2023-12-310001850119us-gaap:FurnitureAndFixturesMember2023-12-310001850119us-gaap:ConstructionInProgressMember2023-12-310001850119ipsc:LabEquipmentMember2023-12-310001850119srt:MaximumMemberipsc:SalesAgreementMember2024-01-012024-03-310001850119us-gaap:EmployeeSeveranceMember2023-01-012023-03-310001850119us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001850119ipsc:AccruedExpensesAndOtherLiabilitiesCurrentMemberipsc:DistributedBioMasterServiceAgreementMember2024-03-310001850119ipsc:AccruedExpensesAndOtherLiabilitiesCurrentMemberipsc:DistributedBioMasterServiceAgreementMember2023-12-310001850119us-gaap:RetainedEarningsMember2024-01-012024-03-310001850119us-gaap:RetainedEarningsMember2023-01-012023-03-310001850119srt:MinimumMember2024-03-310001850119srt:MaximumMember2024-03-310001850119ipsc:FcdiCollaborationAgreementMember2024-01-012024-03-310001850119ipsc:FcdiCollaborationAgreementMember2023-01-012023-03-310001850119ipsc:TimeBasedVestingMember2024-03-310001850119ipsc:UnvestedRestrictedStockWithTimeBasedVestingMember2024-01-012024-03-310001850119ipsc:TimeBasedVestingMember2024-01-012024-03-310001850119us-gaap:RestrictedStockUnitsRSUMember2024-03-310001850119ipsc:UnvestedRestrictedStockWithTimeBasedVestingMember2024-03-310001850119ipsc:ResearchAndDevelopmentServicesMemberipsc:TransactionPriceMember2024-03-310001850119ipsc:OptionRightsMemberipsc:TransactionPriceMember2024-03-310001850119ipsc:TransactionPriceMember2024-03-310001850119ipsc:ResearchAndDevelopmentServicesMember2024-03-310001850119ipsc:OptionRightsMember2024-03-310001850119ipsc:ResearchAndDevelopmentServicesMemberipsc:TransactionPriceMember2023-12-310001850119ipsc:OptionRightsMemberipsc:TransactionPriceMember2023-12-310001850119ipsc:TransactionPriceMember2023-12-310001850119ipsc:ResearchAndDevelopmentServicesMember2023-12-310001850119ipsc:OptionRightsMember2023-12-310001850119us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMember2024-03-310001850119us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateBondSecuritiesMember2024-03-310001850119us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMember2023-12-310001850119us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateBondSecuritiesMember2023-12-310001850119ipsc:Tranche1AdvancesMember2020-09-140001850119ipsc:TermLoanAgreementWithHerculesCapitalIncMember2020-09-140001850119ipsc:PerformanceBasedRestrictedStockUnitsMember2023-04-012023-06-300001850119ipsc:ResearchAndDevelopmentServicesMemberipsc:CumulativeCollaborationRevenueRecognizedMember2024-01-012024-03-310001850119ipsc:CumulativeCollaborationRevenueRecognizedMember2024-01-012024-03-310001850119ipsc:ResearchAndDevelopmentServicesMemberipsc:CumulativeCollaborationRevenueRecognizedMember2023-01-012023-12-310001850119ipsc:CumulativeCollaborationRevenueRecognizedMember2023-01-012023-12-310001850119ipsc:SecuritiesPurchaseAgreementMemberipsc:PrivatePlacementSharesMember2024-04-300001850119ipsc:SalesAgreementMember2024-03-310001850119us-gaap:EmployeeStockMemberipsc:IncentivePlan2021Member2024-03-310001850119ipsc:IncentivePlan2021Member2024-03-3100018501192023-03-3100018501192022-12-310001850119us-gaap:USTreasurySecuritiesMember2024-03-310001850119us-gaap:CorporateBondSecuritiesMember2024-03-310001850119us-gaap:USTreasurySecuritiesMember2023-12-310001850119us-gaap:CorporateBondSecuritiesMember2023-12-310001850119us-gaap:FairValueInputsLevel2Member2024-03-310001850119us-gaap:FairValueInputsLevel1Member2024-03-310001850119us-gaap:FairValueInputsLevel2Member2023-12-310001850119us-gaap:FairValueInputsLevel1Member2023-12-310001850119ipsc:CladeTherapeuticsIncMember2024-04-012024-04-300001850119us-gaap:WarrantMember2024-01-012024-03-310001850119us-gaap:StockOptionMember2024-01-012024-03-310001850119us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-03-310001850119us-gaap:RestrictedStockMember2024-01-012024-03-310001850119ipsc:EarlyExercisedStockOptionsSubjectToFutureVestingMember2024-01-012024-03-310001850119us-gaap:WarrantMember2023-01-012023-03-310001850119us-gaap:StockOptionMember2023-01-012023-03-310001850119us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-03-310001850119us-gaap:RestrictedStockMember2023-01-012023-03-310001850119ipsc:EarlyExercisedStockOptionsSubjectToFutureVestingMember2023-01-012023-03-310001850119us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-03-310001850119us-gaap:RestrictedStockMember2024-01-012024-03-310001850119us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-03-310001850119us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-03-310001850119us-gaap:EmployeeStockOptionMember2024-01-012024-03-310001850119us-gaap:EmployeeStockMember2024-01-012024-03-310001850119us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-03-310001850119us-gaap:RestrictedStockMember2023-01-012023-03-310001850119us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-03-310001850119us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-03-310001850119us-gaap:EmployeeStockOptionMember2023-01-012023-03-310001850119us-gaap:EmployeeStockMember2023-01-012023-03-310001850119us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001850119us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001850119us-gaap:CommonStockMember2023-01-012023-03-310001850119us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001850119us-gaap:CommonStockMember2024-01-012024-03-310001850119ipsc:EmployeeStockOptionsAndRestrictedStockUnitsMemberipsc:IncentivePlan2021Member2024-03-310001850119ipsc:IncentivePlan2021Member2023-01-012023-12-310001850119ipsc:SalesAgreementMember2024-01-012024-03-310001850119ipsc:SecuritiesPurchaseAgreementMember2024-04-300001850119ipsc:IncentivePlan2021Member2024-01-012024-03-310001850119ipsc:EmployeeStockPurchasePlan2021Member2023-01-012023-12-3100018501192023-01-012023-03-310001850119ipsc:IcellInc.SublicenseAgreementMember2020-03-310001850119ipsc:TermLoanAgreementWithHerculesCapitalIncMember2023-05-012023-05-010001850119ipsc:TermLoanAgreementWithHerculesCapitalIncMember2023-05-010001850119ipsc:BristolMyersSquibbCompanyCollaborationAgreementMember2022-01-072022-01-070001850119ipsc:CladeTherapeuticsIncMember2024-04-300001850119srt:MaximumMemberipsc:IcellInc.SublicenseAgreementMember2020-03-310001850119ipsc:DistributedBioMasterServiceAgreementMember2019-06-240001850119ipsc:IcellInc.SublicenseAgreementMember2024-03-310001850119ipsc:DistributedBioMasterServiceAgreementMember2024-03-310001850119ipsc:IcellInc.SublicenseAgreementMember2023-12-310001850119ipsc:FcdiCollaborationAgreementMemberipsc:BristolMyersSquibbCompanyCollaborationAgreementMember2022-01-070001850119ipsc:BristolMyersSquibbCompanyCollaborationAgreementMember2022-01-0700018501192020-09-1400018501192023-12-3100018501192024-03-3100018501192024-05-0100018501192024-01-012024-03-31xbrli:sharesiso4217:USDipsc:Programiso4217:USDxbrli:sharesipsc:itemxbrli:pureipsc:segment

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2024

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _______                      

Commission File Number: 001-40498

Century Therapeutics, Inc.

(Exact Name of Registrant as Specified in its Charter)

Delaware

    

84-2040295

(State or other jurisdiction of
incorporation or organization)

(I.R.S. Employer
Identification No.)

25 N 38th Street, 11th Floor
Philadelphia, Pennsylvania
(Address of principal executive offices)

19104
(Zip Code)

(267) 817-5790

(Registrant’s telephone number, including area code)

Not applicable

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

    

Trading
Symbol(s)

    

Name of each exchange on which registered

Common Stock, $0.0001 par value per share

IPSC

The Nasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  No 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer           

Accelerated filer                  

Non-accelerated filer             

Smaller reporting company

Emerging growth company   

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes   No 

As of May 1, 2024 the registrant had 82,847,375 shares of common stock, $0.0001 par value per share, outstanding.

Table of Contents

 

 

Page

PART I.

FINANCIAL INFORMATION

6

Item 1.

Unaudited Consolidated Financial Statements:

6

Consolidated Balance Sheets as of March 31, 2024 (unaudited) and December 31, 2023

6

Consolidated Statements of Operations and Comprehensive Loss for the three months ended March 31, 2024 and 2023 (unaudited)

7

Consolidated Statements of Changes in Stockholders’ Equity for the three months ended March 31, 2024 and 2023 (unaudited)

8

Consolidated Statements of Cash Flows for the three months ended March 31, 2024 and 2023 (unaudited)

9

Notes to Unaudited Consolidated Financial Statements

10

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

30

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

42

Item 4.

Controls and Procedures

42

PART II.

OTHER INFORMATION

43

Item 1.

Legal Proceedings

43

Item 1A.

Risk Factors

43

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

43

Item 3.

Defaults Upon Senior Securities

43

Item 4.

Mine Safety Disclosures

43

Item 5.

Other Information

44

Item 6.

Exhibits

45

Signatures

46

2

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q and the documents incorporated by reference herein contain forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this Quarterly Report on Form 10-Q or the documents incorporated by reference herein regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “will,” “would,” “could,” “should,” “potential,” “seek,” “evaluate,” “pursue,” “continue,” “design,” “impact,” “affect,” “forecast,” “target,” “outlook,” “initiative,” “objective,” “designed,” “priorities,” “goal,” or the negative of such terms and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements are based on assumptions and expectations that may not be realized and are inherently subject to risks, uncertainties and other factors, many of which cannot be predicted with accuracy and some of which might not even be anticipated.

The forward-looking statements in this Quarterly Report on Form 10-Q include, among other things, statements about:

our ability to raise additional capital to fund our operations and continue the development of our current and future product candidates;
the preclinical and early clinical nature of our business and our ability to successfully advance our current and future product candidates through development activities, preclinical studies, and clinical trials;
our ability to generate revenue from future product sales and our ability to achieve and maintain profitability;
the accuracy of our projections and estimates regarding our expenses, capital requirements, cash utilization, and need for additional financing;
our dependence on the success of our lead product candidate, CNTY-101;
the novelty of our approach to immuno-oncology and autoimmune treatment of cancer, utilizing iPSC-derived natural killer cells, (“iNK cells”) and iPSC-derived T cells, (“iT cells”) and the challenges we will face due to the novel nature of such technology;
the success of competing therapies that are or may become available;
our reliance on the maintenance of our collaborative relationship with FUJIFILM Cellular Dynamics Inc., (“FCDI”) for access to key differentiation and reprogramming technology for the manufacturing and development of our product candidates;
the initiation, progress, success, cost, and timing of our development activities, preclinical studies and clinical trials;
the timing of future investigational new drug, (“IND”) applications and the likelihood of, and our ability to obtain and maintain, regulatory clearance of IND applications for our product candidates;
the timing, scope and likelihood of regulatory filings and approvals, including final regulatory approval of our product candidates;
our reliance on FCDI to be the exclusive manufacturer of certain product candidates, and our ability to manufacture our own product candidates in the future, and the timing and costs of such manufacturing activities;

3

our reliance on the maintenance of our collaborative relationship with Bristol-Myers Squibb Company (“Bristol-Myers Squibb”) in connection with the furtherance of our collaboration programs;
our ability to successfully integrate with the operations of Clade Therapeutics, Inc. (“Clade”) following the acquisition and achieve the anticipated benefits of the acquisition;
the performance of third parties in connection with the development of our product candidates, including third parties conducting our current and future clinical trials as well as third-party suppliers and manufacturers;
our ability to attract and retain strategic collaborators with development, regulatory, and commercialization expertise;
the public opinion and scrutiny of cell-based therapies and its potential impact on public perception of our company and product candidates;
our ability to successfully commercialize our product candidates and develop sales and marketing capabilities, if our product candidates are approved;
the size and growth of the potential markets for our product candidates and our ability to serve those markets;
regulatory developments and approval pathways in the United States and foreign countries for our product candidates;
the potential scope and value of our intellectual property and proprietary rights;
our ability, and the ability of our licensors, to obtain, maintain, defend, and enforce intellectual property and proprietary rights protecting our product candidates, and our ability to develop and commercialize our product candidates without infringing, misappropriating, or otherwise violating the intellectual property or proprietary rights of third parties;
our ability to recruit and retain key members of management and other clinical and scientific personnel;
the volatility of capital markets and other macroeconomic factors, including due to inflationary pressures, banking instability geopolitical tensions or the outbreak of hostilities or war;
the extent to which pandemics, such as the COVID-19 pandemic, or any other global health crises may impact our business, including development activities, preclinical studies, clinical trials, supply chain and labor force; and
developments relating to our competitors and our industry;

We have based these forward-looking statements largely on our current expectations, estimates, forecasts, and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Quarterly Report on Form 10-Q, we cannot guarantee that the future results, levels of activity, performance, or events and circumstances reflected in the forward-looking statements will be achieved or occur at all. You should refer to the section titled “Risk Factors” set forth in Part II, Item 1A of this quarterly Report on Form 10-Q, and in the section titled “Risk Factors” set forth in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2023 for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements.

4

Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

You should read this Quarterly Report on Form 10-Q completely and with the understanding that our actual future results may be materially different from what we expect. We intend the forward-looking statements contained in this Quarterly Report on Form 10-Q to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”).

5

PART I—FINANCIAL INFORMATION

Item 1. Unaudited Consolidated Financial Statements.

CENTURY THERAPEUTICS, INC.

CONSOLIDATED BALANCE SHEETS

(In thousands, except share amounts)

March 31, 2024

December 31, 2023

    

(unaudited)

    

Assets

Current assets

Cash and cash equivalents

$

46,812

$

47,324

Short-term investments

 

145,204

 

125,414

Prepaid expenses and other current assets

 

7,797

 

4,256

Total current assets

 

199,813

 

176,994

Property and equipment, net

 

69,005

 

71,705

Operating lease right-of-use assets

19,314

20,376

Restricted cash

1,979

1,979

Long-term investments

 

57,852

 

89,096

Security deposits and non-current assets

 

544

 

541

Total assets

$

348,507

$

360,691

Liabilities and stockholders’ equity

 

  

 

  

Current liabilities

 

 

  

Accounts payable

$

3,432

$

2,741

Accrued expenses and other liabilities

 

7,532

 

10,149

Deposit liability

491

584

Deferred revenue, current

4,610

4,372

Total current liabilities

 

16,065

 

17,846

Operating lease liability, long term

 

44,251

 

46,658

Security deposit, non-current

20

Deposit liability, non-current

56

Deferred revenue, non-current

110,288

111,381

Total liabilities

 

170,624

 

175,941

Commitments and contingencies (Note 9)

 

  

 

  

Stockholders' equity:

Preferred stock, $ 0.0001 par value, 10,000,000 shares authorized and 0 shares issued and outstanding at March 31, 2024 and December 31, 2023

Common stock, $0.0001 par value, 300,000,000 shares authorized; 64,809,592 and 60,335,701 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively

6

6

Additional paid-in capital

 

861,951

 

840,407

Accumulated deficit

(683,833)

(655,771)

Accumulated other comprehensive (loss) Income

(241)

108

Total stockholders’ equity

177,883

184,750

Total liabilities and stockholders’ equity

$

348,507

$

360,691

See accompanying notes to the consolidated financial statements.

6

CENTURY THERAPEUTICS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Unaudited)

(In thousands, except share and per share amounts)

For the Three Months Ended

For the Three Months Ended

March 31, 2024

March 31, 2023

Collaboration revenue

$

855

$

1,720

Operating expenses

Research and development

23,421

24,899

General and administrative

 

8,743

 

8,902

Total operating expenses

 

32,164

 

33,801

Loss from operations

 

(31,309)

 

(32,081)

Interest expense

 

-

 

(404)

Interest income

3,237

2,623

Other income (expense)

 

11

 

(194)

Total other income

3,248

2,025

Loss before provision for income taxes

(28,061)

(30,056)

Provision for income taxes

(1)

(1,208)

Net loss

$

(28,062)

$

(31,264)

Net loss per common share
Basic and Diluted

(0.45)

(0.53)

Weighted average common shares outstanding
Basic and Diluted

62,296,637

58,610,375

Other comprehensive loss

Net loss

$

(28,062)

$

(31,264)

Unrealized (loss) gain on investments

(351)

1,196

Foreign currency translation gain (loss)

2

(9)

Comprehensive loss

$

(28,411)

$

(30,077)

See accompanying notes to the consolidated financial statements.

7

CENTURY THERAPEUTICS, INC.

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

(Unaudited)

(In thousands, except share amounts)

Accumulated

Additional

Other

Total

Common Stock

Paid-in

Accumulated

Comprehensive

Stockholders’

  

Shares

Amount

Capital

Deficit

Loss

Equity

Balance, December 31, 2023

60,335,701

$

6

$

840,407

$

(655,771)

$

108

$

184,750

Issuance of common stock upon the exercise of stock options and 2021 ESPP

220,647

366

366

Vesting of restricted stock

24,734

Vesting of early exercise stock options

34,900

142

142

Vesting of restricted stock units

109,108

Issuance of common stock upon the exercise of ATM, net of underwriting discounts and commissions and other issuance costs

4,084,502

17,829

17,829

Unrealized loss on investments

(351)

(351)

Foreign currency translation

2

2

Stock based compensation

3,207

3,207

Net loss

(28,062)

(28,062)

Balance, March 31, 2024

64,809,592

$

6

$

861,951

$

(683,833)

$

(241)

$

177,883

Accumulated

Additional

 Other 

Total

Common Stock

Paid-in

Accumulated

Comprehensive

Stockholders’

Shares

  

Amount

Capital

Deficit

Loss

Equity

Balance, December 31, 2022

58,473,660

$

6

$

824,292

$

(519,098)

$

(2,462)

$

302,738

Issuance of common stock upon the exercise of stock options

452,102

448

448

Vesting of restricted stock

95,877

Vesting of early exercise stock options

85,145

 

 

269

 

269

Unrealized gain on investments

1,196

1,196

Foreign currency translation

(9)

(9)

Stock based compensation

3,797

3,797

Net loss

(31,264)

(31,264)

Balance, March 31, 2023

59,106,784

$

6

$

828,806

$

(550,362)

$

(1,275)

$

277,175

See accompanying notes to the consolidated financial statements.

8

CENTURY THERAPEUTICS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(in thousands)

Three Months Ended

Three Months Ended

March 31, 2024

March 31, 2023

    

    

Cash flows from operating activities

 

  

 

  

 

Net loss

$

(28,062)

$

(31,264)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

Depreciation

 

3,226

 

2,908

Amortization of deferred financing cost

56

Non-cash operating lease expense (benefit)

1,542

(738)

Stock based compensation

 

3,207

 

3,797

Amortization/accretion of investments

(1,115)

Change in operating assets and liabilities:

 

 

Escrow deposit

 

 

220

Prepaid expenses and other assets

 

(3,395)

 

(160)

Operating lease liability

(2,186)

3,842

Deferred revenue

(855)

(1,720)

Accounts payable

 

689

 

(2,954)

Accrued expenses and other liabilities

 

(3,319)

 

(3,206)

Non-current security deposit

20

Net cash used in operating activities

 

(30,248)

 

(29,219)

Cash flows from investing activities

 

  

 

  

Acquisition of property and equipment

 

(539)

 

(4,991)

Acquisition of fixed maturity securities, available for sale

 

(35,087)

 

(42,829)

Sale of fixed maturity securities, available for sale

 

47,167

 

79,158

Net cash provided by investing activities

 

11,541

 

31,338

Cash flows from financing activities

 

  

 

  

Proceeds from issuance of common stock and ESPP

366

448

Proceeds from ATM, net of issuance costs

17,829

Proceeds from issuance of shares to collaboration partner

Net cash provided by financing activities

 

18,195

 

448

Net (decrease) increase in cash, cash equivalents, and restricted cash

 

(512)

 

2,567

Cash, cash equivalents and restricted cash, beginning of period

 

49,303

 

86,244

Cash, cash equivalents and restricted cash, end of period

$

48,791

$

88,811

Supplemental disclosure of cash and non-cash operating activities:

Cash paid for interest

$

$

345

Cash paid for income tax

$

$

Supplemental disclosure of non-cash investing and financing activities:

  

 

  

Purchase of property and equipment, accrued and unpaid

$

$

975

See accompanying notes to the consolidated financial statements.

9

CENTURY THERAPEUTICS, INC.

NOTES TO FINANCIAL STATEMENTS

(Unaudited)

(in thousands, except share and per share amounts)

Note 1—Organization and description of the business

Century Therapeutics, Inc. (the “Company”) is an innovative biotechnology company developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies and autoimmune diseases with significant unmet medical need. Since inception, the Company has devoted substantially all of its time and efforts to performing research and development activities, building infrastructure and raising capital. The Company is incorporated in the state of Delaware.

Principles of Consolidation

The consolidated financial statements include the consolidated financial position and consolidated results of operations of the Company and the Company’s subsidiary, Century Therapeutics Canada ULC (“Century Canada”). All intercompany balances and transactions have been eliminated in consolidation.

Liquidity

The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has limited operating history and its prospects are subject to risks, expenses, and uncertainties frequently encountered by companies in the biotechnology and pharmaceutical industries. These risks include, but are not limited to, the uncertainty of availability of additional financing and the uncertainty of achieving future profitability.

Since inception, the Company has incurred net losses and negative cash flows from operations. During the three months ended March 31, 2024, the Company incurred a net loss of $28,062. During the three months ended March 31, 2024, the Company used $30,248 of cash in operations. Cash and cash equivalents and investments were $249,868 at March 31, 2024. Management expects to incur additional losses in the future to fund its operations and conduct product research and preclinical and clinical development and recognizes the need to raise additional capital to fully implement its business plan. The Company believes it has adequate cash and financial resources to operate for at least the next 12 months from the date of issuance of these consolidated financial statements.

Note 2—Summary of significant accounting policies and basis of presentation

Basis of presentation

The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and with the interim period reporting requirements of Form 10-Q and Article 10 of Regulation S-X. The consolidated balance sheet as of March 31, 2024, and the consolidated statements of operations and comprehensive loss, consolidated statements of changes in stockholders’ equity, and the consolidated statements of cash flows for the three months ended March 31, 2024 and 2023 are unaudited, but, in the opinion of management, include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.  The results for any interim period are not necessarily indicative of results for the year ending December 31, 2024 or for any other subsequent interim period.  The consolidated balance sheet at December 31, 2023 has been derived from the Company’s audited consolidated financial statements.

10

Certain prior year information has been reclassified to conform to the fiscal year 2024 presentation.

Segment information

Operating segments are identified as components of an enterprise for which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions on how to allocate resources and assess performance. The Company views its operations and manages the business as one operating segment.

Use of estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. Estimates and assumptions are primarily made in relation to the valuations supporting stock compensation, the estimation of the incremental borrowing rate for operating leases and standalone selling prices of performance obligations in collaboration agreements. If actual results differ from the Company’s estimates, or to the extent these estimates are adjusted in future periods, the Company’s results of operations could either benefit from, or be adversely affected by, any such change in estimate.

Concentration of credit risk and other risks and uncertainties

Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist of cash, cash equivalents, U.S. Treasury bills and bonds, as well as corporate bonds. Cash and cash equivalents, as well as short and long-term investments include a checking account and asset management accounts held by a limited number of financial institutions. At times, such deposits may be in excess of insured limits. As of March 31, 2024 and December 31, 2023, the Company has not experienced any losses on its deposits of cash and cash equivalents.

The Company’s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company’s future operating results and cause actual results to vary materially from expectations include, but are not limited to, rapid technological change, uncertainty of market acceptance of its products, competition from substitute products and larger companies, protection of proprietary technology, strategic relationships, and dependence on key individuals.

Products developed by the Company require clearances from the U.S. Food and Drug Administration (the “FDA”) or other international regulatory agencies prior to commercial sales. There can be no assurance the Company’s future products will receive the necessary clearances. If the Company was denied clearance, clearance was delayed, or if the Company was unable to maintain clearance, it could have a material adverse impact on the Company.

Fair value of financial instruments

The Company discloses and recognizes the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements). The guidance establishes three levels of the fair value hierarchy as follows:

Level 1

Inputs that reflect unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date;

11

Level 2

Inputs other than quoted prices that are observable for the asset or liability either directly or indirectly, including inputs in markets that are not considered to be active;

Level 3

Inputs are unobservable in which there is little or no market data available, which require the reporting entity to develop its own assumptions that are unobservable.

Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.

Cash and cash equivalents

Management considers all highly liquid investments with an insignificant interest rate risk and original maturities of three months or less to be cash equivalents.

Restricted cash

As of March 31, 2024 and December 31, 2023, the Company had $1,979 in cash on deposit to secure certain lease commitments. Restricted cash is recorded separately in the Company’s consolidated balance sheets.

The following provides a reconciliation of the Company’s cash, cash equivalents, and restricted cash as reported in the consolidated balance sheets to the amounts reported in the consolidated statements of cash flows:

    

March 31, 2024

    

December 31, 2023

Cash and cash equivalents

$

46,812

$

47,324

Restricted cash

1,979

1,979

Cash, cash equivalents, and restricted cash

$

48,791

$

49,303

Investments

The Company invests in fixed maturity securities including U.S. Treasury bills and bonds as well as corporate bonds. The investments are classified as available-for-sale and reported at fair value. Unrealized gains or losses are determined by comparing the fair market value of the securities with their cost or amortized cost. Realized gains and losses on investments are recorded on the trade date and are included in the statement of operations. Unrealized gains and losses on investments are recorded in other comprehensive loss on the consolidated statements of operations and comprehensive loss. The cost of securities sold is based on the specified identification method. Investment income is recognized as earned and discounts or premiums arising from the purchase of debt securities are recognized in investment income using the interest method over the remaining term of the security. Securities with an original maturity date greater than three months that mature within one year of the balance sheet date are classified as short-term, while investments with a maturity date greater than one year are classified as long-term.

Property and equipment, net

Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which is generally five years. Leasehold improvements are amortized over the shorter of the asset’s useful life or the remaining term of the lease. Construction in progress includes direct cost related to the construction of leasehold improvements and is stated at original cost. Such costs are not depreciated until the asset is completed and placed into service. Once the asset is placed into service, these capitalized costs will be allocated to leasehold improvements and will be depreciated over the shorter of the asset’s useful life or the remaining term of the lease. Computer software and equipment includes implementation costs for cloud-based software and network equipment.

12

Expenditures for major additions and improvements are capitalized, while minor replacements, maintenance, and repairs are charged to expense as incurred. When property is retired or otherwise disposed of, the costs and accumulated depreciation are removed from the respective accounts, with any resulting gain or loss recognized concurrently.

Research and development expenses

Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, payroll taxes, employee benefits, stock compensation, materials, supplies, rent, depreciation on and maintenance of research equipment with alternative future use, and the cost of services provided by outside contractors. All costs associated with research and development are expensed as incurred.

Clinical trial costs are a component of research and development expenses. The Company expenses costs for its clinical trial activities performed by third parties, including clinical research organizations and other service providers, as they are incurred, based upon estimates of the work completed over the life of the individual study in accordance with associated agreements. The Company uses information it receives from internal personnel and outside service providers to estimate the clinical trial costs incurred.

Stock-based compensation

Employees, consultants and members of the Board of Directors of the Company have received stock options and restricted stock of the Company. The Company recognizes the cost of the stock-based compensation incurred as its employees and board members vest in the awards. The Company accounts for stock-based compensation arrangements in accordance with provisions of Accounting Standards Codification (“ASC”) 718, Compensation—Stock Compensation. ASC 718 requires the recognition of compensation expense, using a fair-value based method, for costs related to all share-based payments including stock options. ASC 718 requires companies to estimate the fair value of share-based payment awards on the date of grant using an option-pricing model. The Company uses the Black-Scholes option-pricing model (“Black Scholes”) to determine the fair value of options granted. The Company’s stock-based awards are subject to service-based vesting conditions and performance-based vesting conditions. Compensation expense related to awards to employees and directors with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term. For performance-based awards, the Company reassesses at each reporting date whether achievement of the performance condition is probable and accrues compensation expense if and when achievement of the performance condition is probable.

Black Scholes requires inputs based on certain subjective assumptions, including (i) the expected stock price volatility, (ii) the expected term of the award, (iii) the risk-free interest rate and (iv) expected dividends. The historical volatility is calculated based on a period of time commensurate with expected term assumption. The risk-free interest rate is based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. Forfeitures are recognized as they occur.

Foreign currency translation

The reporting currency of the Company is the U.S. dollar. The functional currency of Century Canada is the Canadian dollar. Assets and liabilities of Century Canada are translated into U.S. dollars based on exchange rates at the end of each reporting period. Expenses are translated at average exchange rates during the reporting period. Gains and losses arising from the translation of assets and liabilities are included as a component of accumulated other comprehensive loss or income on the Company’s consolidated balance sheets. Gains and losses resulting from foreign currency transactions are reflected within the Company’s

13

consolidated statements of operations and comprehensive loss. The Company has not utilized any foreign currency hedging strategies to mitigate the effect of its foreign currency exposure.

Intercompany payables and receivables are considered to be long-term in nature and any change in balance due to foreign currency fluctuation is included as a component of the Company’s consolidated comprehensive loss and accumulated other comprehensive loss within the Company’s consolidated balance sheets.

Basic and diluted net loss per common shares

Basic net loss per common share is computed by dividing net loss applicable to common shareholders by the weighted-average number of common shares outstanding during the period. The Company computes diluted net loss per common share by dividing the net loss applicable to common shareholders by the sum of the weighted-average number of common shares outstanding during the period plus the potential dilutive effects of its warrants, restricted stock and stock options to purchase common shares, but such items are excluded if their effect is anti-dilutive. Because the impact of these items is anti-dilutive during periods of net loss, there were no differences between the Company’s basic and diluted net loss per common share for the three months ended March 31, 2024 and 2023.

Collaboration revenue

The Company may enter into collaboration and licensing agreements with strategic partners for research and development, manufacturing, and commercialization of its product candidates. Payments under these arrangements may include non-refundable, upfront fees; reimbursement of certain costs; customer option fees for additional goods or services; payments upon the achievement of development, regulatory, and commercial milestones; sales of product at certain agreed-upon amounts; and royalties on product sales.

The Company recognizes revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers, (“ASC 606”). This standard applies to all contracts with customers. When an agreement falls under the scope of other standards, such as ASC Topic 808, Collaborative Arrangements, or (“ASC 808”), the Company will apply the recognition, measurement, presentation, and disclosure guidance in ASC 606 to the performance obligations in the agreements if those performance obligations are with a customer. Revenue recognized by analogizing to ASC 606 is recorded as collaboration revenue on the statements of operations.

Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under a collaboration agreement, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations on a relative stand-alone selling price basis; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.

As part of the accounting for these arrangements, the Company must use its judgment to determine the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price. The estimation of the stand-alone selling price may include such estimates as forecasted revenues and costs, development timelines, discount rates, and probabilities of regulatory and commercial success. The Company also applies significant judgment when evaluating whether contractual obligations represent distinct performance obligations, allocating transaction price to performance obligations within a contract, determining when performance obligations have been met, assessing the recognition and future reversal of variable consideration and determining and applying appropriate methods of measuring progress for performance obligations satisfied over time. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, current. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, non-current.

14

If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services, the goods and services underlying the customer options are not considered to be performance obligations at the outset of the arrangement, as they are contingent upon option exercise. The Company evaluates the customer options for material rights or options to acquire additional goods or services for free or at a discount. If the customer options are not determined to represent a material right, no transaction price is allocated to these options and the Company will account for these options at that time they are exercised. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement.

The obligations under the Company’s collaboration agreements may include research and development services to be performed by the Company for or on behalf of the customer. Amounts allocated to these performance obligations are recognized as the Company performs these obligations, and revenue is measured based on an inputs method of costs incurred to date of budgeted costs. Under certain circumstances, the Company may be reimbursed for certain expenses incurred under the research and development services.

At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the statements of operations in the period of adjustment.

Recent accounting pronouncements

In December 2023, the FASB issued ASU No. 2023-09, "Income Taxes (Topic 740): Improvements to Income Tax Disclosures ("ASU 2023-09"). ASU 2023-09 requires entities to provide additional information in their tax rate reconciliation and additional disclosures about income taxes paid by jurisdiction. ASU 2023-09 is effective for annual reporting periods beginning after December 15, 2024, with early adoption permitted. The guidance should be applied prospectively, but entities have the option to apply it retrospectively for each period presented. The Company is currently evaluating the impact of adopting this new accounting guidance.

Note 3—Reduction in force

In January 2023, the Company's Board of Directors approved, and management implemented, a new portfolio prioritization and capital allocation strategy. The resulting changes included pausing investments in CNTY-103 for glioblastoma as well as a discovery program in hematologic malignancies. The Company has shifted focus to CNTY-101 and will accelerate key programs, including one follow-on candidate for lymphoma, CNTY-102, CNTY-107 for Nectin-4+ solid tumors, and CNTY-101 in moderate to severe Systemic Lupus Eythematosus (“SLE”). In addition, the Company continues its partnered programs with Bristol Myers Squibb. The restructuring plan resulted in a reduction in the Company's workforce of approximately 25%. In connection with the restructuring plan, lab operations in Seattle and Hamilton, Ontario were closed and research activities were consolidated in Philadelphia.

15

During the three months ended March 31, 2023, the Company incurred $2,032 of cash-based expenses related to employee severances, benefits and related costs. Of these amounts, $292 related to general and administrative expense, while $1,740 related to R&D expense. In addition, the Company recorded non-cash stock-based compensation charge of $581 related to modification of equity awards for employees impacted by the restructuring during the year ended December 31, 2023. Of these amounts, $171 related to G&A expense, while $410 related to R&D expense. There were no remaining outstanding liabilities related to the reduction in force at March 31, 2024.

Note 4—Financial instruments and fair value measurements

The following table sets forth the Company’s assets that were measured at fair value as of March 31, 2024 by level within the fair value hierarchy:

    

Level 1

    

Level 2

    

Level 3

    

Total

Cash equivalents

$

41,492

$

41,492

U.S. Treasury

 

 

17,838

 

 

17,838

Corporate bonds

 

 

185,218

 

 

185,218

Total

$

41,492

$

203,056

$

$

244,548

The following table sets forth the Company’s assets that were measured at fair value as of December 31, 2023, by level within the fair value hierarchy:

    

Level 1

    

Level 2

    

Level 3

    

Total

Cash equivalents

$

42,263

$

42,263

U.S. Treasury

 

 

26,114

 

 

26,114

Corporate bonds

 

 

188,396

 

 

188,396

Total

$

42,263

$

214,510

$

$

256,773

There were no transfers between levels during the period ended March 31, 2024. The Company uses the services of its investment manager, which uses widely accepted models for assumptions in valuing securities with inputs from major third-party data providers.

The Company classifies all of its investments in fixed maturity debt securities as available-for-sale and, accordingly, are carried at estimated fair value.

The amortized cost, gross unrealized gains and losses, and fair value of investments in fixed maturity securities are as follows as of March 31, 2024:

    

    

Gross 

    

Gross

    

Unrealized

 Unrealized 

Amortized Cost

 Gains

Losses

Fair Value

U.S. Treasury

$

17,855

$

$

(17)

$

17,838

Corporate bonds

 

185,329

 

128

 

(239)

 

185,218

Total

$

203,184

$

128

$

(256)

$

203,056

16

The amortized cost, gross unrealized gains and losses, and fair value of investments in fixed maturity securities are as follows as of December 31, 2023:

    

Gross 

    

Gross 

    

Unrealized

Unrealized

    

Amortized Cost

 Gains

 Losses

Fair Value

U.S. Treasury

$

26,070

$

44

$

$

26,114

Corporate bonds

 

188,219

 

399

 

(222)

 

188,396

Total

$

214,289

$

443

$

(222)

$

214,510

The following table provides the maturities of our fixed maturity available-for-sale securities:

     

March 31, 2024

     

December 31, 2023

Less than one year

$

145,204

$

125,414

One to five years

 

57,852

 

89,096

$

203,056

$

214,510

The Company has evaluated the unrealized losses on the fixed maturity securities and determined that they are not attributable to credit risk factors. For fixed maturity securities, losses in fair value are viewed as temporary if the fixed maturity security can be held to maturity and it is reasonable to assume that the issuer will be able to service the debt, both as to principal and interest.

At March 31, 2024 and December 31, 2023, the Company had 52 and 25 available-for-sale investment debt securities in an unrealized loss position without an allowance for credit losses, respectively. Unrealized losses on corporate debt securities have not been recognized into income because the issuers’ bonds are of high credit quality (rated BBB+ or higher) and the decline in fair value is largely due to market conditions and or changes in interest rates. Management does not intend to sell and it is likely that management will not be required to sell the securities prior to the anticipated recovery of their amortized cost basis. The issuers continue to make timely payments on the bonds. The fair value is expected to recover as the bonds approach maturity.

As of March 31, 2024 and December 31, 2023, accrued interest receivable on available-for-sale investment debt securities totaling $1,583 and $1,570, respectively, is excluded from the estimate of credit losses and is included in prepaid expenses and other current assets.

Note 5—Property and equipment, net

The following is a summary of property and equipment, net:

     

March 31, 2024

    

December 31, 2023

Lab equipment

$

29,928

$

29,597

Leasehold improvements

 

61,136

 

60,862

Construction in progress

 

 

124

Computer software and equipment

 

2,899

 

2,899

Furniture and fixtures

 

1,061

 

1,061

Total

95,024

94,543

Less: Accumulated depreciation

 

(26,019)

 

(22,838)

Property and equipment, net

$

69,005

$

71,705

Depreciation expense was $3,226 and $2,908 for the three months ended March 31, 2024 and 2023, respectively.

17

Note 6—Accrued expenses and other liabilities

The following is a summary of accrued expenses:

     

March 31, 2024

    

December 31, 2023

Payroll and bonuses

$

2,868

    

$

6,496

Accrued clinical trial related costs

356

470

Professional and legal fees

 

2,043

 

1,642

Operating lease liability, current

2,215

1,513

Other

 

50

 

28

Total accrued expenses and other liabilities

$

7,532

$

10,149

Note 7—Long-term debt

On September 14, 2020, the Company entered into a $10,000 Term Loan Agreement (as amended, the “Loan Agreement”) with Hercules Capital, Inc. (“Hercules”). Pursuant to the terms of the Loan Agreement, the Company borrowed $10,000 (the “Tranche 1 Advance”) from the lenders at closing. The Company granted Hercules a lien on substantially all of the Company’s assets, excluding intellectual property.

On May 1, 2023, the Company prepaid the Loan Agreement in full. The total amount paid to Hercules in connection with the prepayment was $10,617, which included all outstanding principal, accrued and unpaid interest and end of term and prepayment charges (“the Payoff Amount”). The Payoff Amount included a prepayment charge of $100 (equal to 1.0% of the outstanding principal), and an end of term fee of $395, which is being recognized as interest expense and accreted over the term of the Loan Agreement using the effective interest method. Upon receipt by Hercules of the Payoff Amount on May 1, 2023, all obligations, covenants, debts and liabilities of the Company under the Loan Agreement were satisfied and discharged in full, and the Loan Agreement was terminated.

The Company issued to Hercules warrants to purchase up to an aggregate of 16,112 shares of common stock. The warrants are exercisable for a period of ten years from the date of the issuance of each warrant at a per share exercise price equal to $13.96, subject to certain adjustments as specified in the warrants. The fair value of the warrants at issuance was $46. The Company accounted for the warrants as equity, and the fair value is recorded in additional paid-in capital. The warrant value is also recorded as a debt discount and classified as a contra-liability on the consolidated balance sheet and amortized to interest expense.

Interest expense attributable to the Loan Agreement is as follows:

For the Three Months Ended

For the Three Months Ended

    

March 31, 2024

    

March 31, 2023

Interest expense

$

$

348

Amortization of debt issuance costs, including end of term fee accretion

 

 

56

$

$

404

18

Note 8 – Bristol-Myers Squibb Collaboration

On January 7, 2022, the Company entered into the Collaboration Agreement with Bristol-Myers Squibb to collaborate on the research, development and commercialization of iNK and iT cell programs for hematologic malignancies and solid tumors (“Collaboration Program,” and each product candidate a “Development Candidate”). The Collaboration Agreement is within the scope of ASC 808, Collaborative Arrangements as both parties are active participants in the arrangement and are exposed to significant risks and rewards. While this arrangement is in the scope of ASC 808, the Company analogizes to ASC 606 for the accounting for the Collaboration Agreement, including for the delivery of goods and services (i.e., units of account). Revenue recognized by analogizing to ASC 606 is recorded as collaboration revenue in the statements of operations.

Pursuant to the Collaboration Agreement, the Company and Bristol-Myers Squibb will initially collaborate on two Collaboration Programs focused on acute myeloid leukemia (“AML”) and multiple myeloma (“MM”), and Bristol-Myers Squibb has the option to add up to two additional Collaboration Programs for an additional fee. The Company is responsible for generating Development Candidates for each Collaboration Program, and Bristol-Myers Squibb has the option to elect to exclusively license the Development Candidates for pre-clinical development, clinical development and commercialization on a worldwide basis (“License Option”). Following Bristol-Myers Squibb’s exercise of the License Option, the Company will be responsible for performing IND-enabling studies, supporting Bristol-Myers Squibb’s preparation and submission of an IND, and manufacturing of clinical supplies until completion of a proof of concept clinical trial. Bristol-Myers Squibb will be responsible for all regulatory, clinical, manufacturing (after the proof of concept clinical trial) and commercialization activities for such Development Candidates worldwide. The Company has the option to co-promote Development Candidates generated from certain specified Collaboration Programs.

Under the terms of the Collaboration Agreement, Bristol-Myers Squibb made a non-refundable, upfront cash payment of $100,000 and will pay an exercise fee upon the exercise of the License Option (“Licensed Program” and product candidates developed under a Licensed Program, “Licensed Products”). For each Licensed Program, Bristol-Myers Squibb will pay up to $235,000 in milestone payments upon the first achievement of certain development and regulatory milestones and will pay up to $500,000 per Licensed Product in net sales-based milestone payments. Bristol-Myers Squibb will also pay the Company tiered royalties per Licensed Product as a percentage of net sales in the high-single digits to low-teens, subject to reduction for biosimilar competition, compulsory licensing and certain third party license costs. If Century exercises its co-promote option, such royalty percentage will be increased to low-teens to high-teens in respect of the sales of the co-promoted Licensed Products in the United States. The royalty term shall terminate on a Licensed Product-by-Licensed Product and country-by-country basis on the latest of (i) the 12-year anniversary of the first commercial sale of such Licensed Product in such country, (ii) the expiration of any regulatory exclusivity period that covers such Licensed Product in such country, and (iii) the expiration of the last-to-expire licensed patent of the Company or a jointly owned patent that covers such the Licensed Product in such country. After expiration of the applicable royalty term for a Licensed Product in a country, all licenses granted by the Company to Bristol-Myers Squibb for such Licensed Product in such country will be fully paid-up, royalty-free, perpetual and irrevocable.

In connection with the Collaboration Agreement, Bristol-Myers Squibb purchased 2,160,760 shares of the Company’s common stock at a price per share of $23.14, for an aggregate purchase price of $50,000. In determining the fair value of the common stock issued to Bristol-Myers Squibb, the Company considered the closing price of the common stock on the date of the transaction and included a lack of marketability discount because the shares are subject to certain restrictions. The Company determined the common stock purchase represented a premium of $7.82 per share, or $23,187 in the aggregate (“Equity Premium”), and the remaining $26,813 was recorded as issuance of common stock in stockholders’ equity.

The Company identified the following commitments under the arrangement: (i) research and development services (“R&D Services”) under each of the two initial Collaboration Programs and (ii) Bristol-Myers Squibb’s License Option to elect to exclusively license the Development Candidates for each of the two initial Collaboration Programs. The Company determined that these four commitments represent distinct

19

performance obligations for purposes of recognizing revenue and will recognize revenue as the Company fulfills each performance obligation.

The Company determined that the upfront payment and Equity Premium constitute the transaction price at the inception of the Collaboration Agreement. The future potential development and regulatory milestone payments were fully constrained at contract inception as the risk of significant revenue reversal related to these amounts has not yet been resolved. The achievement of the future potential milestones is not within the Company’s control and is subject to certain research and development success and therefore carries significant uncertainty. The Company will reevaluate the likelihood of achieving these milestones at the end of each reporting period and adjust the transaction price in the period the risk is resolved. In addition, the Company will recognize any consideration related to sales-based milestones and royalties when the subsequent sales occur.

The total transaction price of $123,187 was allocated to the performance obligations based on their estimated standalone selling price on January 7, 2022. The stand-alone selling price of the research and development services was estimated using the expected cost-plus margin approach, and the stand-alone selling price of the License Options was based on a discounted cash flow approach and considered several factors including, but not limited to, discount rate, development timeline, regulatory risks, estimated market demand, and future revenue potential using an adjusted market approach. The allocated transaction price is recognized as revenue in one of two ways:

Research and development services: The Company recognizes the portion of the transaction price allocated to each of the research and development performance obligations as the research and development services are provided, using an inputs method, in proportion to costs incurred to date for each research development target as compared to total costs incurred and expected to be incurred in the future to satisfy the underlying obligation related to each research and development target. The transfer of control occurs over this period and, in management’s judgment, is the best measure of progress towards satisfying the performance obligation.
License option rights: The transaction price allocated to the license options rights, which are considered material rights to license and commercialize the underlying research and development target, are deferred until the period that Bristol-Myers Squibb elects to exercise or elects to not exercise its option or when the option to exercise expires.

The following table summarizes the allocation of the total transaction price to the identified performance obligations under the arrangement, and the amount of the transaction price unsatisfied as of March 31, 2024:

Cumulative collaboration

Deferred

Performance obligations:

Transaction price

revenue recognized

collaboration revenue

Option rights

$

109,164

$

-

$

109,164

Research and development services

14,023

(8,289)

5,734

Total

123,187

(8,289)

114,898

Less current portion of deferred revenue

-

-

(4,610)

Total long-term deferred revenue

$

123,187

$

(8,289)

$

110,288

20

The following table summarizes the allocation of the total transaction price to the identified performance obligations under the arrangement, and the amount of the transaction price unsatisfied as of December 31, 2023:

Cumulative collaboration

Deferred

Performance obligations:

Transaction price

revenue recognized

collaboration revenue

Option rights

$

109,164

$

-

$

109,164

Research and development services

14,023

(7,434)

6,589

Total

123,187

(7,434)

115,753

Less current portion of deferred revenue

-

-

(4,372)

Total long-term deferred revenue

$

123,187

$

(7,434)

$

111,381

Note 9—Commitments and contingencies

From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues a liability for such matters when future expenditures are probable and such expenditures can be reasonably estimated.

Distributed Bio Master Service Agreement

On July 24, 2019, the Company entered into a Master Service Agreement with Distributed Bio, Inc (“DBio”), whereby DBio will screen for protein binders that bind to specific therapeutic targets (the “Master Service Agreement”). The Company pays for such services according to a payment schedule, and if the Company brings the protein binders into the clinic for further development, DBio will receive milestone payments of up to $16,100 in total for each product as the products move through the clinical development and regulatory approval processes. No milestone payments were due since the inception of the agreement.

The Company had $58 within accounts payable as of March 31, 2024 and $106 as of December 31, 2023, in its consolidated balance sheets related to the Master Service Agreement.

iCELL Inc. Sublicense Agreement

In March 2020, the Company entered into a Sublicense Agreement with iCELL Inc (“iCELL”) whereby iCELL granted the Company a license of certain patents and technology. The Company will pay iCELL royalties in the low single digits on net sales of the licensed product. In addition to the earned royalties, the Company will pay sales milestones, not to exceed $70,000, for the sales of the licensed product. iCELL is also eligible to receive payments of up to $4,250 in development and regulatory approval milestone payments. No milestones or royalties were due in 2024 or 2023.

Note 10—Leases

The Company has commitments under operating leases for certain facilities used in its operations. The Company maintains security deposits on certain leases in the amounts of $410 and $1,260 within security deposits and non-current assets in its consolidated balance sheets at March 31, 2024 and December 31, 2023, respectively. The Company’s leases have initial lease terms ranging from 5 to 16 years. Certain lease agreements contain provisions for future rent increases.

21

The following table reflects the components of lease expense:

For the

For the

Three Months Ended

Three Months Ended

March 31, 2024

March 31, 2023

Operating lease expense:

    

    

Fixed lease cost

$

1,085

$

1,395

Variable lease cost

 

450

 

125

Short term lease expense

594

Total operating lease expense

$

1,535

$

2,114

The following table reflects supplemental balance sheet information related to leases:

    

As of

As of

    

    

March 31, 

    

December 31, 

Location in Balance Sheet

2024

2023

Operating lease right-of-use asset, net

 

Operating lease right-of-use assets

$

19,314

$

20,376

Operating lease liability, current

 

Accrued expenses and other liabilities

$

2,215

$

1,513

Operating lease liability, long-term

 

Operating lease liability, long-term

 

44,251

 

46,658

Total operating lease liability

 

  

$

46,466

$

48,171

The following table reflects supplement lease term and discount rate information related to leases:

    

As of March 31, 2024

     

As of December 31, 2023

 

Weighted-average remaining lease terms - operating leases

 

7.3 years

7.6 years

Weighted-average discount rate - operating leases

 

9.9

%

9.9

%

The following table reflects supplemental cash flow information related to leases as of the periods indicated:

For the Three Months Ended

For the Three Months Ended

     

March 31, 2024

     

March 31, 2023

Cash paid for amounts included in the measurement of lease liabilities

 

  

 

  

Operating cash flows from operating leases

$

(2,186)

$

(31)

Right-of-use assets obtained in exchange for lease obligations:

$

$

The following table reflects future minimum lease payments under noncancelable leases as of March 31, 2024:

    

Operating Leases

2024

$

5,900

2025

 

8,421

2026

 

7,931

2027

 

8,125

2028

 

8,325

Thereafter

 

43,163

Total lease payments

 

81,865

Less: Imputed interest

 

(27,423)

Less: Tenant incentive receivable

(7,976)

Total

$

46,466

22

Note 11—Income taxes

During the three months ended March 31, 2024, the Company recorded no income tax benefits for the net operating losses incurred or for the research and development tax credits generated in the U.S. due to its uncertainty of realizing a benefit from those items. During the three months ended March 31, 2023, the Company recorded a tax provision of $1.2 mill